LATUDA Drug Insight and Market Forecast - 2032

LATUDA Drug Insight and Market Forecast − 2032

“LATUDA Drug Insight and Market Forecast – 2032” report provides comprehensive insights about LATUDA for schizophrenia in the seven major markets. A detailed picture of the LATUDA for schizophrenia in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the LATUDA for schizophrenia. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the LATUDA market forecast analysis for schizophrenia in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in schizophrenia.

Drug Summary

LATUDA (lurasidone), an oral atypical antipsychotic from a chemical class of benzisothiazol derivatives, is approved for schizophrenia treatment in patients 13 years or older. It changes the chemical effects in the brain. LATUDA is not approved for use in psychotic conditions related to dementia. Lurasidone may increase the death risk in older adults with dementia-related conditions.

Lurasidone works primarily as a result of the activity of the parent drug. Its pharmacokinetic properties are dose-proportional within a total dose of 20–160 mg/day, and the steady-state concentrations are reached within 7 days of initiation of therapy. The elimination half-life of the parent compound is approximately 18 hours.

Dosage and administration

Adults: The recommended starting dose of LATUDA is 40 mg once daily. Initial dose titration is not required. LATUDA is effective in a dose range of 40–160 mg/day. The maximum recommended dose is 160 mg/day.

Adolescents (13–17 years): The recommended starting dose of LATUDA is 40 mg once daily. Initial dose titration is not required. LATUDA is effective in a dose range of 40–80 mg/day. The maximum recommended dose is 80 mg/day.

Mechanism of action

The mechanism of action of lurasidone in the treatment of schizophrenia and bipolar depression is unclear. However, its efficacy in schizophrenia and bipolar depression could be mediated through a combination of central dopamine D2 and serotonin type 2 (5HT2A) receptor antagonism

Scope of the Report

The report provides insights into:

A comprehensive product overview including the LATUDA description, mechanism of action, dosage and administration, research and development activities in schizophrenia.

Elaborated details on LATUDA regulatory milestones and other development activities have been provided in this report.

The report also highlights the LATUDA research and development activities in schizophrenia across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around LATUDA.

The report contains forecasted sales of for schizophrenia till 2032.

Comprehensive coverage of the late-stage emerging therapies for schizophrenia.

The report also features the SWOT analysis with analyst views for LATUDA in schizophrenia.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

LATUDA Analytical Perspective by DelveInsight

In-depth LATUDA Market Assessment

This report provides a detailed market assessment of LATUDA for schizophrenia in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

LATUDA Clinical Assessment

The report provides the clinical trials information of LATUDA for schizophrenia covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for schizophrenia is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence LATUDA dominance.

Other emerging products for schizophrenia are expected to give tough market competition to LATUDA and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of LATUDA in schizophrenia.

Our in-depth analysis of the forecasted sales data of LATUDA from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the LATUDA in schizophrenia.

Key Questions

What is the product type, route of administration and mechanism of action of LATUDA?

What is the clinical trial status of the study related to LATUDA in schizophrenia and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the LATUDA development?

What are the key designations that have been granted to LATUDA for schizophrenia?

What is the forecasted market scenario of LATUDA for schizophrenia?

What are the forecasted sales of LATUDA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

What are the other emerging products available and how are these giving competition to LATUDA for schizophrenia?

Which are the late-stage emerging therapies under development for the treatment of schizophrenia?